Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreas Adenocarcinoma: early-phase trial registry
9 of 11 indexed Pancreas Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 9 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Pancreas Adenocarcinoma: 11 US clinical trials tracked, 9 recruiting.
Pancreas Adenocarcinoma is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Wake Forest University Health Sciences, running 2 of these trials.
Enrollment posture brief
Registry condition pancreas-adenocarcinoma
OPEN 9 | RECR 82% | LATE 0 | EARLY 8 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Gynecologic Cancers (82% recruiting · 11 trials)
Pancreas Adenocarcinoma lists 9 open slots (82% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreas Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreas Adenocarcinoma is recruiting above its size-band peers.
9 of 11 indexed trials (81.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pancreas Adenocarcinoma research.
Wake Forest University Health Sciences accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreas Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.
-
Pancreas Adenocarcinoma research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Genetic Testing Decision Aid
Massachusetts General Hospital
NCT05470920
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
Wake Forest University Health Sciences
NCT05376592
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
NCT05825066
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Yale University
NCT07282912
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03977233
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Dartmouth-Hitchcock Medical Center
NCT07043270
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Loma Linda University
NCT03492671
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
Capital Health System
NCT04998552
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
NCT04331041
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
University of Kansas Medical Center
NCT05915351
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreas Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreas Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreas Adenocarcinoma page
11 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Pancreas Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Wake Forest University Health Sciences sponsors the most Pancreas Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Wake Forest University Health Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreas Adenocarcinoma condition card totals 11 registered trials; most-linked intervention Research blood draw; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.